UBS Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $189M | Buy |
627,004
+168,134
| +37% | +$50.7M | 0.02% | 699 |
|
|
2026
Q1 | $152M | Sell |
458,870
-366,970
| -44% | -$125M | 0.02% | 763 |
|
|
2025
Q4 | $328M | Buy |
825,840
+337,636
| +69% | +$149M | 0.05% | 349 |
|
|
2025
Q3 | $223M | Sell |
488,204
-55,282
| -10% | -$22.5M | 0.03% | 525 |
|
|
2025
Q2 | $177M | Buy |
543,486
+264,848
| +95% | +$73.3M | 0.03% | 596 |
|
|
2025
Q1 | $75.2M | Sell |
278,638
-11,328
| -4% | -$2.91M | 0.01% | 1122 |
|
|
2024
Q4 | $68.2M | Buy |
289,966
+134,295
| +86% | +$35.3M | 0.01% | 1199 |
|
|
2024
Q3 | $42.8M | Sell |
155,671
-912
| -0.6% | -$237K | 0.01% | 1258 |
|
|
2024
Q2 | $38M | Buy |
156,583
+32,120
| +26% | +$5.07M | 0.01% | 1217 |
|
|
2024
Q1 | $18.6M | Buy |
124,463
+33,990
| +38% | +$5.67M | ﹤0.01% | 1753 |
|
|
2023
Q4 | $17.3M | Buy |
90,473
+20,571
| +29% | +$3.5M | 0.01% | 1677 |
|
|
2023
Q3 | $12.4M | Sell |
69,902
-3,641
| -5% | -$695K | ﹤0.01% | 1825 |
|
|
2023
Q2 | $14M | Buy |
73,543
+33,439
| +83% | +$6.63M | ﹤0.01% | 1731 |
|
|
2023
Q1 | $8.03M | Sell |
40,104
-7,247
| -15% | -$1.52M | ﹤0.01% | 2067 |
|
|
2022
Q4 | $11.3M | Buy |
47,351
+1,655
| +4% | +$353K | ﹤0.01% | 1830 |
|
|
2022
Q3 | $9.15M | Buy |
45,696
+20,629
| +82% | +$3.93M | ﹤0.01% | 1862 |
|
|
2022
Q2 | $3.66M | Sell |
25,067
-2,909
| -10% | -$413K | ﹤0.01% | 2634 |
|
|
2022
Q1 | $4.57M | Sell |
27,976
-61,497
| -69% | -$9.37M | ﹤0.01% | 2619 |
|
|
2021
Q4 | $15.2M | Buy |
89,473
+67,281
| +303% | +$12.5M | ﹤0.01% | 1784 |
|
|
2021
Q3 | $4.19M | Buy |
22,192
+3,543
| +19% | +$665K | ﹤0.01% | 2864 |
|
|
2021
Q2 | $3.16M | Sell |
18,649
-2,573
| -12% | -$377K | ﹤0.01% | 3136 |
|
|
2021
Q1 | $3M | Buy |
21,222
+82
| +0.4% | +$12.3K | ﹤0.01% | 3144 |
|
|
2020
Q4 | $2.75M | Sell |
21,140
-756
| -3% | -$101K | ﹤0.01% | 3081 |
|
|
2020
Q3 | $3.19M | Sell |
21,896
-2,492
| -10% | -$354K | ﹤0.01% | 2624 |
|
|
2020
Q2 | $3.61M | Sell |
24,388
-17,538
| -42% | -$2.36M | ﹤0.01% | 2329 |
|
|
2020
Q1 | $4.56M | Buy |
41,926
+9,146
| +28% | +$1.06M | ﹤0.01% | 2008 |
|
|
2019
Q4 | $3.77M | Sell |
32,780
-38,285
| -54% | -$3.82M | ﹤0.01% | 2874 |
|
|
2019
Q3 | $5.71M | Buy |
71,065
+42,701
| +151% | +$3.38M | ﹤0.01% | 2255 |
|
|
2019
Q2 | $2.06M | Sell |
28,364
-20,270
| -42% | -$1.56M | ﹤0.01% | 3120 |
|
|
2019
Q1 | $4.54M | Sell |
48,634
-55,999
| -54% | -$4.68M | ﹤0.01% | 2288 |
|
|
2018
Q4 | $7.63M | Buy |
104,633
+11,771
| +13% | +$905K | ﹤0.01% | 1799 |
|
|
2018
Q3 | $8.13M | Buy |
92,862
+38,830
| +72% | +$3.91M | ﹤0.01% | 1947 |
|
|
2018
Q2 | $5.32M | Sell |
54,032
-43,989
| -45% | -$4.36M | ﹤0.01% | 2291 |
|
|
2018
Q1 | $11.7M | Buy |
98,021
+18,107
| +23% | +$2.33M | 0.01% | 1561 |
|
|
2017
Q4 | $10.2M | Buy |
79,914
+36,548
| +84% | +$4.59M | ﹤0.01% | 1705 |
|
|
2017
Q3 | $5.09M | Sell |
43,366
-22,701
| -34% | -$1.94M | ﹤0.01% | 2187 |
|
|
2017
Q2 | $5.27M | Buy |
66,067
+4,082
| +7% | +$261K | ﹤0.01% | 2106 |
|
|
2017
Q1 | $3.18M | Sell |
61,985
-50,301
| -45% | -$2.32M | ﹤0.01% | 2490 |
|
|
2016
Q4 | $4.2M | Buy |
112,286
+48,686
| +77% | +$2.04M | ﹤0.01% | 2251 |
|
|
2016
Q3 | $4.31M | Sell |
63,600
-32,240
| -34% | -$2.27M | ﹤0.01% | 2158 |
|
|
2016
Q2 | $5.32M | Buy |
95,840
+54,805
| +134% | +$3.45M | ﹤0.01% | 1904 |
|
|
2016
Q1 | $2.58M | Sell |
41,035
-73,320
| -64% | -$4.87M | ﹤0.01% | 2446 |
|
|
2015
Q4 | $10.8M | Buy |
114,355
+57,018
| +99% | +$5.29M | 0.01% | 1357 |
|
|
2015
Q3 | $4.61M | Buy |
57,337
+24,531
| +75% | +$2.73M | ﹤0.01% | 1991 |
|
|
2015
Q2 | $3.93M | Buy |
32,806
+9,470
| +41% | +$1.13M | ﹤0.01% | 2319 |
|
|
2015
Q1 | $2.44M | Sell |
23,336
-11,298
| -33% | -$1.14M | ﹤0.01% | 2757 |
|
|
2014
Q4 | $3.36M | Buy |
+34,634
| New | +$3.21M | ﹤0.01% | 2419 |
|
Other funds holding ALNY
UBS Group's ALNY Position: Q2 2026 in Review
UBS Group increased its Alnylam Pharmaceuticals (ALNY) stake by 37% in Q2 2026, buying an estimated $50.7M and bringing the position to 627,004 shares worth $189M. The position accounts for 0.02% of the portfolio, ranked #699.
UBS Group first reported a position in ALNY in Q4 2014 and has held it in 47 quarters since. The position peaked at $328M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- UBS Group held 627,004 shares of Alnylam Pharmaceuticals worth $189M as of Q2 2026.
- UBS Group bought 168,134 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $50.7M.
- Alnylam Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q2 2026, its #699 holding.
- UBS Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Alnylam Pharmaceuticals position peaked at $328M in Q4 2025.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.